MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$2,788K
Free Cash flow
-$18,482K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from the issuance of de...
    • Proceeds from issuance of common...
    • Equity-based compensation
    • Others
Negative Cash Flow Breakdown
    • Change in fair value of warrants
    • Net loss
    • Accrued expenses and other curre...
    • Others
Cash Flow
2025-09-30
2025-06-30
Net loss
-8,378
-48,638
Depreciation
61
125
Equity-based compensation
1,476
3,176
Non-cash interest expense
886
253
Amortization of right of use lease asset
169
336
Foreign currency loss (gain)
98
-479
Change in fair value of warrants
-9,846
2,587
Prepaid expenses and other current assets
975
636
Other non-current assets
13
882
Accounts payable
50
877
Lease liability
-139
-418
Accrued expenses and other current liabilities
-1,671
-152
Net cash used in operating activities
-18,478
-42,893
Purchase of property and equipment
4
54
Net cash used in investing activities
-4
-54
Proceeds from the issuance of debt
14,714
11,720
Payments of debt issuance costs
18
233
Proceeds from issuance of common stock upon exercise of stock options
2
-
Proceeds from issuance of common stock in connection with at-the-market program, net of issuance costs of 134
6,572
-
Net cash provided by financing activities
21,270
11,487
Net decrease in cash, cash equivalents and restricted cash
2,788
-31,460
Effect of exchange rate changes on cash
-695
-
Cash and cash equivalents at beginning of period
60,299
-
Cash and cash equivalents at end of period
30,932
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from theissuance of debt$14,714K Proceeds from issuance ofcommon stock in...$6,572K Proceeds from issuance ofcommon stock upon...$2K Net cash provided byfinancing activities$21,270K Canceled cashflow$18K Net decrease incash, cash...$2,788K Canceled cashflow$18,482K Payments of debt issuancecosts$18K Equity-based compensation$1,476K Non-cash interestexpense$886K Amortization of right of uselease asset$169K Depreciation$61K Accounts payable$50K Net cash used inoperating activities-$18,478K Net cash used ininvesting activities-$4K Canceled cashflow$2,642K Change in fair value ofwarrants-$9,846K Net loss-$8,378K Accrued expenses andother current...-$1,671K Purchase of property andequipment$4K Prepaid expenses andother current assets$975K Lease liability-$139K Foreign currency loss(gain)$98K Other non-currentassets$13K

IO Biotech, Inc. (IOBT)

IO Biotech, Inc. (IOBT)